Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Shanghai Jiao Tong University School of Medicine | OTHER |
| Chinese Academy of Sciences | OTHER_GOV |
| Shanxi Medical University | OTHER |
| Central South University |
Not provided
Not provided
Not provided
Not provided
Major Depressive Disorder is one of the most common mental diseases,which increases health-care costs and the financial burden to families and societies. Considering its complex clinical symptoms and diversity of comorbidity, depressive disorder's recognition，diagnosis，and antihistone are based on symptomatology,which is lack of multidimensional diagnosis technique based on clinical pathological characteristics,as well as lack of individualized therapy strategy based on quantified evaluation. Besides, other physical diseases，such as nervous system diseases, cardiovascular diseases，endocrine diseases, have the high comorbidity of depressive disorder. However，there is no precise diagnosis technique or standardized therapy strategy. With all those taken into consideration,our study is aimed to adopt E-mental health and m-Health to explore multi-dimensional diagnosis, individualized therapy and management technique based on molecular biology,nerve electrophysiology，and neuroimaging technology etc.
Four parts included in our study:
Part 1:The research, development and verification of indicators based on biomarkers and clinical characteristics to guide the diagnosis and treatment of depressive disorders
Part 2: The development,transition and application of hierarchical model diagnostic technique for physical diseases combined with depressive disorder.
Part3: The development and application of comprehensive prevention， diagnosis,and intervention model of depressive disorder.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Depression/underload 1 | Experimental | This group would be treated with fluoxetine from the minimum dosage. |
|
| Depression/underload 2 | Experimental | This group would be treated with fluoxetine combined with cognitive behavior treatment |
|
| Depression/underload 3 | Experimental | This group would be treated with fluoxetine and amfebutamone from the minimum dosage. |
|
| Depression/underload 4 | Experimental | This group would be treated with fluoxetine + physical treatment to help to cure depressive disorder. |
|
| Atypical 1 | Experimental | This group would be treated with fluvoxamine from the minimum dosage. |
|
| Atypical 2 |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Fluoxetine | Drug | Fluoxetine is one kind of selective serotonin reuptake inhibitor(SSRIs), whose effect is much better than other non-underload subtypes compared with underload subtypes.So patients would be treated with fluoxetine only. |
| Measure | Description | Time Frame |
|---|---|---|
| Change from baseline in levels of microRNA，apolipoproteins, meta ion (Composite measure) | The potential biomarkers in our study include microRNA,apolipoproteins,metallic ion etc.We use quantitative analysis technique to test miRNA,proteins and metallic ion by patients' blood and urines before interventions and after interventions. | at 2,4,6,8,12 week. |
| Measure | Description | Time Frame |
|---|---|---|
| Hamilton Depression Scale(HADA) scores,reductive ratio | HADA,created by Hamilton in 1960,is one of the most common questionnaires to evaluate the severity of depression and the efficiency of medicine. we adopt the Hamilton Depression Scale(HADA)to evaluate different medicines efficiency by analyzing reductive ratio.The investigators record the total scores of HADA at baseline and 2,4,6,8,12 week. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Xiaohua Liu | Contact | +8613918061085 | liuxh_2005@126.com |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| ShanghaiMHC | Recruiting | Shanghai | China |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 36189181 | Derived | Liu H, Wu X, Wang Y, Liu X, Peng D, Wu Y, Chen J, Su Y, Xu J, Ma X, Li Y, Shi J, Yang X, Rong H, Forti MD, Fang Y. TNF-alpha, IL-6 and hsCRP in patients with melancholic, atypical and anxious depression: an antibody array analysis related to somatic symptoms. Gen Psychiatr. 2022 Sep 8;35(4):e100844. doi: 10.1136/gpsych-2022-100844. eCollection 2022. | |
| 35018097 |
Not provided
Not provided
To share raw data via the network platform named Clinical Trial Management Public Platform within 1year after the trial finished. And the platform website address is http://www.medresman.org
Not provided
Not provided
Not provided
Not provided
| Type | Date | Date Unknown |
|---|---|---|
| Release | Jan 18, 2026 | |
| Reset | Feb 5, 2026 | |
| Release | Jun 12, 2026 |
Not provided
| OTHER |
| Second Military Medical University | OTHER |
| Peking University Sixth Hospital | OTHER |
| First Affiliated Hospital Xi'an Jiaotong University | OTHER |
| First Affiliated Hospital of Kunming Medical University | OTHER |
| Air Force Military Medical University, China | OTHER |
| Zhejiang University | OTHER |
| Wuhan Mental Health Centre | OTHER |
| Corning Hospital, Shenzhen City | UNKNOWN |
| the First Specialized Subject Hospital of Harbin | UNKNOWN |
| Renmin Hospital of Wuhan University | OTHER |
| Seventh People's Hospital of Hangzhou | OTHER |
| Shandong Mental Health Center | OTHER |
Part 2: all patients before receiving any medicine treatment are divided into four groups which adopt different therapy strategies :treatment with fluvoxamine, fluoxetine, mirtazapine and treatment as usual(TAU).Meanwhile，patients with different subtypes of depressive disorder were randomly assigned to different therapy groups.Each therapy groups contains 50 participants.Therefore, the total sample size is 50*12+200=800.
Part3:To find out efficiency of different kinds of therapy strategies.p=60%, error=5%,a-0.05,the amount of samples nearly is:867,considering the nearly 30% expulsion rate, the final total sample size is 867+260=1127.Therefore,sample size in each group is nearly 376.
Part4:p=60%,error=0.05, a=0.05, exculsion rate=30%,N=867+260=1127.the amount of samples of each group is 1127/3=nearly 400.
Not provided
Not provided
patients with depressive disorder were randomly assigned to different therapy groups or TAU therapy group based on different depressive disorders subtypes.
This group would be treated with fluoxetine + cognitive behavior treatment |
|
| Atypical 3 | Experimental | This group would be treated with fluvoxamine + lithium from the minimum dosage. |
|
| Atypical 4 | Experimental | This group would be treated with fluvoxamine + lithium + physical treatment |
|
| Anxiety/somatization 1 | Experimental | This group would be treated with mirtazapine/selective serotonin-norepinephrine reuptake inhibitors（SNRIs） from the minimum dosage. |
|
| Anxiety/somatization 2 | Experimental | This group would be treated with mirtazapine/SNRIs + cognitive behavior treatment. |
|
| Anxiety/somatization 3 | Experimental | This group would be treated with mirtazapine + SNRIs from the minimum dosage. |
|
| Anxiety/somatization 4 | Experimental | This group would be treated with mirtazapine + SNRIs + physical treatment. |
|
| treatment as usual(TAU) | Experimental | The investigators recommend therapy strategies according to accessible methods. |
|
| fluoxetine + cognitive-behavioral treatment（CBT） | Combination Product | the investigators would recommend fluoxetine to help to cure depressive disorder.And CBT is a very effective way for patients to alleviate or relieve clinical symptoms during episode stage. |
|
| fluoxetine + Amfebutamone | Drug | Amfebutamone is one kind of SNRIs, and it shows much better therapy effect on patients with exhaustion /dizziness.So the investigators recommend these two drugs to help to cure patients with depressive disorder. |
|
| physical treatment+fluoxetine+amfebutamone | Combination Product | the investigators recommend drug(fluoxetine and amfebutamone) and physical treatment as intervention. |
|
| Fluvoxamine | Drug | Fluvoxamine could inhibit CYP1A2 and CYP2C19 and affect the metabolism of melatonin, and help to release symptoms of depressive disorder with sleep problems. |
|
| Lithium+fluvoxamine | Drug | the investigators recommend lithium as a mood stabilizer and use fluvoxamine to affect the level of melatonin. |
|
| fluvoxamine + lithium + physical therapy | Combination Product | the investigators recommend depressants and mood stabilizers as well as physical therapy to help to cure depressive disorder. |
|
| Cognitive behavior treatment +fluvoxamine | Combination Product | the investigators recommend behavioral therapy as well as drugs. |
|
| Mirtazapine/SNRIs | Drug | Mirtazapine is one kind of antagonist of a2 adrenergic receptors and could block 5-hydroxytryptamine2 and 5-hydroxytryptamine3,help to release symptoms like anxiety or somatization.Besides, SNRIs could also make similar effect on patients.Therefore, the investigators recommend mirtazapine/SNRIs to treat patients with depressive disorder. |
|
| mirtazapine+ Cognitive behavior treatment | Combination Product | the investigators recommend CBT and mirtazapine as interventions.The dosage and frequency would depend on patients' severity of symptoms . |
|
| mirtazapine + SNRIs | Drug | the investigator recommend mirtazapine and SNRIs to treat patients with major depressive disorder. |
|
| mirtazapine + SNRIs + physical therapy | Combination Product | the investigators would manage to use drugs and physical treatment to help to release the symptoms of depressive disorder. |
|
| TAU(treat as usual) | Other | patients in this group would receive therapy strategies according to their symptoms and preference. |
|
| at 0,2,4,6,8,12 week. |
| Patient health questionnaire(PHQ-9):the clinical remission ratio | PHQ-9 is a self-report scale composed of 9 items to evaluate the state of depression.The investigators in our study record the total scores of PHQ-9 at 0,2,4,6,8,12 week to analyze the clinical remission ratio. | change from baseline PHQ-9 total scores at 2,4,6,8,12 week |
| life event scale(LES) | LES is one of the common questionnaires to evaluate individual's mental and stress stimulation in daily life.The investigators record the total scores of LES at baseline. | at baseline |
| social support scale(SSS) | SSS is one of the common questionnaires to evaluate individual's social support and social relationship network to explore the correlation between social support and mental health. the investigators in our study record the total scores of SSS at baseline. | at baseline |
| dysfunctional attitudes scales(DAS) | The DAS is a self-report scale composed of 40 items to assess typical, stable depressogenic attitudes or schemas that make individuals vulnerable to depression. The investigators in our study record the total scores od DAS at baseline. | at baseline |
| the gray matter volume, | The investigators in our study use voxel-based morphometry (VBM8)to record the gray matter volume. | change from baseline neuroimaging data at 2,4,6,8,12 week |
| fractional amplitudes of low-frequency fluctuation(fLAFF) | The investigators in our study use region-of-interest(ROI)to record fLAFF. | change from baseline neuroimaging data at 2,4,6,8,12 week |
| Neuroelectrophysiological examination: electroencephalogram(EEG) | EEG is used to record individual's brain activity. The investigators in our study record individual's brain wave. | at baseline |
| Neuroelectrophysiological examination:electrocardiograph(ECG) | ECG is used to record the individual's cardiac cycle. | at baseline. |
| Wang Y, Liu X, Peng D, Wu Y, Su Y, Xu J, Ma X, Li Y, Shi J, Cheng X, Rong H, Fang Y. A Preliminary Study of Different Treatment Strategies for Anxious Depression. Neuropsychiatr Dis Treat. 2022 Jan 4;18:11-18. doi: 10.2147/NDT.S320091. eCollection 2022. |
| 33116533 | Derived | Liu X, Wang Y, Peng D, Zhang H, Zheng Y, Wu Y, Su YA, Liu M, Ma X, Li Y, Shi J, Cheng X, Rong H, Fang Y. The Developmental and Translational Study on Biomarkers and Clinical Characteristics-based Diagnostic and Therapeutic Identification of Major Depressive Disorder: Study Protocol for a Multicenter Randomized Controlled Trial in China. Neuropsychiatr Dis Treat. 2020 Oct 9;16:2343-2351. doi: 10.2147/NDT.S271842. eCollection 2020. |
| Reset | Jul 9, 2026 |
Not provided
| Release Date | Unrelease Date | Unrelease Date Unknown | Reset Date | MCP Release Number |
|---|---|---|---|---|
| Jan 18, 2026 | Feb 5, 2026 | |||
| Jun 12, 2026 | Jul 9, 2026 |
| ID | Term |
|---|---|
| D003866 | Depressive Disorder |
| ID | Term |
|---|---|
| D019964 | Mood Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| D005473 | Fluoxetine |
| D016642 | Bupropion |
| D016666 | Fluvoxamine |
| D008094 | Lithium |
| D026741 | Physical Therapy Modalities |
| D000078785 | Mirtazapine |
| D000068760 | Serotonin and Noradrenaline Reuptake Inhibitors |
| ID | Term |
|---|---|
| D011437 | Propylamines |
| D000588 | Amines |
| D009930 | Organic Chemicals |
| D011427 | Propiophenones |
| D007659 | Ketones |
| D010091 | Oximes |
| D006898 | Hydroxylamines |
| D008672 | Metals, Alkali |
| D004602 | Elements |
| D007287 | Inorganic Chemicals |
| D019565 | Metals, Light |
| D008670 | Metals |
| D013812 | Therapeutics |
| D012046 | Rehabilitation |
| D003984 | Dibenzazepines |
| D006575 | Heterocyclic Compounds, 3-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D006571 | Heterocyclic Compounds |
| D014179 | Neurotransmitter Uptake Inhibitors |
| D049990 | Membrane Transport Modulators |
| D045504 | Molecular Mechanisms of Pharmacological Action |
| D020228 | Pharmacologic Actions |
| D020164 | Chemical Actions and Uses |
| D018377 | Neurotransmitter Agents |
| D045505 | Physiological Effects of Drugs |
Not provided
Not provided